NCT04127851View on ClinicalTrials.gov

Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

July 14, 2021

Study Completion Date

October 14, 2021

Conditions
Dry EyeDry Eye Syndromes
Interventions
DRUG

TJO-018 (HA 0.15%)

TJO-018 / one drop / 6 times daily in both eyes

DRUG

Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)

Cyclosporine / one drop / twice daily in both eyes carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes

DRUG

TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%

TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes

Trial Locations (1)

Unknown

Taejoon Pharmaceutical Co., Ltd., Seoul

All Listed Sponsors
lead

Taejoon Pharmaceutical Co., Ltd.

INDUSTRY

NCT04127851 - Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients | Biotech Hunter | Biotech Hunter